Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.46
RHHBY's Cash to Debt is ranked higher than
50% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. RHHBY: 0.46 )
RHHBY' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 0.46

Equity to Asset 0.26
RHHBY's Equity to Asset is ranked higher than
53% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RHHBY: 0.26 )
RHHBY' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.59
Current: 0.26

0.1
0.59
F-Score: 5
Z-Score: 3.80
M-Score: -2.79
WACC vs ROIC
8.23%
37.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.26
RHHBY's Operating margin (%) is ranked higher than
96% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. RHHBY: 28.26 )
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.53   Max: 33.69
Current: 28.26

4.53
33.69
Net-margin (%) 18.71
RHHBY's Net-margin (%) is ranked higher than
93% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. RHHBY: 18.71 )
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.67   Max: 30.16
Current: 18.71

-13.67
30.16
ROE (%) 49.73
RHHBY's ROE (%) is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. RHHBY: 49.73 )
RHHBY' s 10-Year ROE (%) Range
Min: -16.17   Max: 102.95
Current: 49.73

-16.17
102.95
ROA (%) 14.01
RHHBY's ROA (%) is ranked higher than
96% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. RHHBY: 14.01 )
RHHBY' s 10-Year ROA (%) Range
Min: -5.78   Max: 17.58
Current: 14.01

-5.78
17.58
ROC (Joel Greenblatt) (%) 71.03
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. RHHBY: 71.03 )
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.9   Max: 84.52
Current: 71.03

6.9
84.52
Revenue Growth (3Y)(%) 5.00
RHHBY's Revenue Growth (3Y)(%) is ranked higher than
77% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. RHHBY: 5.00 )
RHHBY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.3   Max: 391.7
Current: 5

-2.3
391.7
EBITDA Growth (3Y)(%) 3.10
RHHBY's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 828 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. RHHBY: 3.10 )
RHHBY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -5.1   Max: 333.3
Current: 3.1

-5.1
333.3
EPS Growth (3Y)(%) -0.50
RHHBY's EPS Growth (3Y)(%) is ranked higher than
79% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. RHHBY: -0.50 )
RHHBY' s 10-Year EPS Growth (3Y)(%) Range
Min: -3.8   Max: 343.8
Current: -0.5

-3.8
343.8
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

RHHBY Guru Trades in Q1 2014

Ken Fisher 1,803,070 sh (+99.00%)
Bill Frels 2,138,396 sh (+5.45%)
» More
Q2 2014

RHHBY Guru Trades in Q2 2014

Bill Frels 2,184,810 sh (+2.17%)
Ken Fisher 1,813,443 sh (-49.71%)
» More
Q3 2014

RHHBY Guru Trades in Q3 2014

Bill Frels 2,391,096 sh (+9.44%)
Ken Fisher 1,891,406 sh (+4.30%)
» More
Q4 2014

RHHBY Guru Trades in Q4 2014

Ken Fisher 2,823,025 sh (+49.26%)
Bill Frels 2,609,371 sh (+9.13%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.80
RHHBY's P/E(ttm) is ranked higher than
96% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 24.80 )
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.05   Max: 37.26
Current: 24.8

13.05
37.26
Forward P/E 2.27
RHHBY's Forward P/E is ranked higher than
96% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 2.27 )
N/A
PE(NRI) 24.60
RHHBY's PE(NRI) is ranked higher than
97% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 24.60 )
RHHBY' s 10-Year PE(NRI) Range
Min: 13.05   Max: 37.09
Current: 24.6

13.05
37.09
P/B 11.80
RHHBY's P/B is ranked lower than
51% of the 1612 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. RHHBY: 11.80 )
RHHBY' s 10-Year P/B Range
Min: 2.64   Max: 22.21
Current: 11.8

2.64
22.21
P/S 4.79
RHHBY's P/S is ranked higher than
88% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. RHHBY: 4.79 )
RHHBY' s 10-Year P/S Range
Min: 2.38   Max: 6.44
Current: 4.79

2.38
6.44
PFCF 18.30
RHHBY's PFCF is ranked higher than
97% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 18.30 )
RHHBY' s 10-Year PFCF Range
Min: 8.6   Max: 39.65
Current: 18.3

8.6
39.65
POCF 14.41
RHHBY's POCF is ranked higher than
97% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 14.41 )
RHHBY' s 10-Year POCF Range
Min: 6.98   Max: 25.93
Current: 14.41

6.98
25.93
EV-to-EBIT 17.48
RHHBY's EV-to-EBIT is ranked higher than
97% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 17.48 )
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 32
Current: 17.48

7.9
32
PEG 6.47
RHHBY's PEG is ranked higher than
97% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 6.47 )
RHHBY' s 10-Year PEG Range
Min: 0.25   Max: 7.66
Current: 6.47

0.25
7.66
Shiller P/E 24.00
RHHBY's Shiller P/E is ranked higher than
98% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 24.00 )
RHHBY' s 10-Year Shiller P/E Range
Min: 13.35   Max: 110.34
Current: 24

13.35
110.34
Current Ratio 1.35
RHHBY's Current Ratio is ranked higher than
53% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. RHHBY: 1.35 )
RHHBY' s 10-Year Current Ratio Range
Min: 1.35   Max: 3.75
Current: 1.35

1.35
3.75
Quick Ratio 1.01
RHHBY's Quick Ratio is ranked higher than
53% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. RHHBY: 1.01 )
RHHBY' s 10-Year Quick Ratio Range
Min: 1.01   Max: 3.22
Current: 1.01

1.01
3.22
Days Inventory 182.80
RHHBY's Days Inventory is ranked higher than
82% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 182.80 )
RHHBY' s 10-Year Days Inventory Range
Min: 109.1   Max: 245.45
Current: 182.8

109.1
245.45
Days Sales Outstanding 65.90
RHHBY's Days Sales Outstanding is ranked higher than
83% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. RHHBY: 65.90 )
RHHBY' s 10-Year Days Sales Outstanding Range
Min: 65.9   Max: 86.72
Current: 65.9

65.9
86.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.77
RHHBY's Dividend Yield is ranked higher than
88% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 1.03 vs. RHHBY: 2.77 )
RHHBY' s 10-Year Dividend Yield Range
Min: 0.74   Max: 4.55
Current: 2.77

0.74
4.55
Dividend Payout 0.73
RHHBY's Dividend Payout is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 0.73 )
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.72
Current: 0.73

0.21
0.72
Dividend growth (3y) 5.70
RHHBY's Dividend growth (3y) is ranked higher than
77% of the 124 Companies
in the Global Biotechnology industry.

( Industry Median: 11.10 vs. RHHBY: 5.70 )
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 27.3
Current: 5.7

0
27.3
Yield on cost (5-Year) 4.21
RHHBY's Yield on cost (5-Year) is ranked higher than
83% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. RHHBY: 4.21 )
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 1.11   Max: 6.84
Current: 4.21

1.11
6.84
Share Buyback Rate -0.50
RHHBY's Share Buyback Rate is ranked higher than
93% of the 977 Companies
in the Global Biotechnology industry.

( Industry Median: -9.70 vs. RHHBY: -0.50 )
RHHBY' s 10-Year Share Buyback Rate Range
Min: 78.7   Max: -0.8
Current: -0.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.80
RHHBY's Price/DCF (Projected) is ranked higher than
98% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 1.80 )
RHHBY' s 10-Year Price/DCF (Projected) Range
Min: 1.27   Max: 7.13
Current: 1.8

1.27
7.13
Price/Median PS Value 1.20
RHHBY's Price/Median PS Value is ranked higher than
85% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. RHHBY: 1.20 )
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 1.29
Current: 1.2

0.65
1.29
Earnings Yield (Greenblatt) 5.70
RHHBY's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. RHHBY: 5.70 )
RHHBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 12.7
Current: 5.7

3.1
12.7
Forward Rate of Return (Yacktman) 8.77
RHHBY's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 15.51 vs. RHHBY: 8.77 )
RHHBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 79.2
Current: 8.77

2.2
79.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany, 0QQ6.UK, 0QOK.UK, ROG N.Mexico,
Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience. It has more than 66 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals and Chugai, whereas Genentech as the former third segment has been integrated into Roche Pharmaceuticals. The Diagnostics Division consists of the following four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Roche’s Oncology Drugs Drive Its Revenue Northwards In Q1 Apr 24 2015 
Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
Small Cap Biotech Growth Stocks For 2015 Mar 05 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
Roche In Expansion Mode Jan 19 2015 
Why Organovo is A Safe Buy? Dec 18 2014 
Is Organovo A Safe Buy? Dec 08 2014 


More From Other Websites
Roche Beats on Q1 Sales driven by Oncology & Immunology - Analyst Blog Apr 23 2015
Roche Revenue Lifted by Cancer Drugs Apr 22 2015
Roche Reports First-Quarter Sales That Beat Estimates Apr 22 2015
Seeing price pressure in Europe: Roche CEO Apr 22 2015
Bina Technologies and AstraZeneca Announce Collaborative Agreement for Global Deployment of Bina’s... Apr 21 2015
OTC Markets Group Announces First Quarter 2015 Performance of OTCQX and OTCQB Indexes, OTCM ADR... Apr 16 2015
Roche Acquires CAPP Medical to Strengthen Cancer Diagnosis - Analyst Blog Apr 14 2015
Ventana Medical Systems, Inc. and Astellas Pharma join forces to leverage novel companion diagnostic... Apr 14 2015
Roche strengthens oncology translational research pipeline by acquiring CAPP Medical Apr 13 2015
Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog Apr 10 2015
Roche's Avastin's Label Expanded in EU for Cervical Cancer - Analyst Blog Apr 09 2015
Celldex Initiates Study on Varlilumab for Metastatic Melanoma - Analyst Blog Apr 07 2015
Ariosa's Harmony™ Prenatal Test shown to be superior to conventional pregnancy screening for Down... Apr 02 2015
Ariosa's Harmony™ Prenatal Test shown to be superior to conventional pregnancy screening for Down... Apr 02 2015
Canaccord Hot And Cold On Deals By Teva Pharmaceutical, ImmunoGen Mar 31 2015
Roche introduces thermal shift assay application for LightCycler 1536 instrument Mar 31 2015
Ohr Pharmaceutical Crashes on Disappointing Eye Drug Data - Analyst Blog Mar 30 2015
Analyst Discounts Chances For OHR Pharmaceutical Eye Drug Mar 27 2015
Can Pharma Conquer The Consumer The Way Apple Did? This App Might Help Mar 25 2015
This Biotech Is A Prime Buyout Candidate Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK